BioMarin Pharmaceutical Inc. (BMRN) Releases Paradigm Changing Data - Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $130 at Jefferies
May 28, 2019 10:07 AM EDTJefferies analyst Eun Yang raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $130.00 (from $125.00) while maintaining a Buy rating.
Valrox updated data supports potential US launch by YE20... MoreBioMarin Pharmaceutical Inc. (BMRN) PT Raised to $133 at Credit Suisse; Data Re-Awakens M&A Thesis
May 28, 2019 10:05 AM EDTCredit Suisse analyst Martin Auster raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $133.00 (from $131.00) while maintaining a Outperform rating.
Nudged up valrox PoS to 75% (from 65%) and have a peak/recurring revenue assumption of $1.7b/~$1b.Think this data... More